BACKGROUND: A blood-based test that could be used as a screen for Alzheimer disease (AD) may enable early intervention and better access to treatment. OBJECTIVE: To apply a multiplex immunoassay panel to identify plasma biomarkers of AD using plasma samples from the Alzheimer's Disease Neuroimaging Initiative cohort. DESIGN: Cohort study. SETTING: The Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project. PARTICIPANTS: Plasma samples at baseline and at 1 year were analyzed from 396 (345 at 1 year) patients with mild cognitive impairment, 112 (97 at 1 year) patients with AD, and 58 (54 at 1 year) healthy control subjects. MAIN OUTCOME MEASURES: Multivariate and univariate statistical analyses were used to examine differences across diagnostic groups and relative to the apolipoprotein E (ApoE) genotype. RESULTS: Increased levels of eotaxin 3, pancreatic polypeptide, and N-terminal protein B-type brain natriuretic peptide were observed in patients, confirming similar changes reported in cerebrospinal fluid samples of patients with AD and MCI. Increases in tenascin C levels and decreases in IgM and ApoE levels were also observed. All participants with Apo ε3/ε4 or ε4/ε4 alleles showed a distinct biochemical profile characterized by low C-reactive protein and ApoE levels and by high cortisol, interleukin 13, apolipoprotein B, and gamma interferon levels. The use of plasma biomarkers improved specificity in differentiating patients with AD from controls, and ApoE plasma levels were lowest in patients whose mild cognitive impairment had progressed to dementia. CONCLUSIONS: Plasma biomarker results confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B-type brain natriuretic peptide in patients with AD and mild cognitive impairment. Incorporation of plasma biomarkers yielded high sensitivity with improved specificity, supporting their usefulness as a screening tool. The ApoE genotype was associated with a unique biochemical profile irrespective of diagnosis, highlighting the importance of genotype on blood protein profiles.
BACKGROUND: A blood-based test that could be used as a screen for Alzheimer disease (AD) may enable early intervention and better access to treatment. OBJECTIVE: To apply a multiplex immunoassay panel to identify plasma biomarkers of AD using plasma samples from the Alzheimer's Disease Neuroimaging Initiative cohort. DESIGN: Cohort study. SETTING: The Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project. PARTICIPANTS: Plasma samples at baseline and at 1 year were analyzed from 396 (345 at 1 year) patients with mild cognitive impairment, 112 (97 at 1 year) patients with AD, and 58 (54 at 1 year) healthy control subjects. MAIN OUTCOME MEASURES: Multivariate and univariate statistical analyses were used to examine differences across diagnostic groups and relative to the apolipoprotein E (ApoE) genotype. RESULTS: Increased levels of eotaxin 3, pancreatic polypeptide, and N-terminal protein B-type brain natriuretic peptide were observed in patients, confirming similar changes reported in cerebrospinal fluid samples of patients with AD and MCI. Increases in tenascin C levels and decreases in IgM and ApoE levels were also observed. All participants with Apo ε3/ε4 or ε4/ε4 alleles showed a distinct biochemical profile characterized by low C-reactive protein and ApoE levels and by high cortisol, interleukin 13, apolipoprotein B, and gamma interferon levels. The use of plasma biomarkers improved specificity in differentiating patients with AD from controls, and ApoE plasma levels were lowest in patients whose mild cognitive impairment had progressed to dementia. CONCLUSIONS: Plasma biomarker results confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B-type brain natriuretic peptide in patients with AD and mild cognitive impairment. Incorporation of plasma biomarkers yielded high sensitivity with improved specificity, supporting their usefulness as a screening tool. The ApoE genotype was associated with a unique biochemical profile irrespective of diagnosis, highlighting the importance of genotype on blood protein profiles.
Authors: E C degli Uberti; M Bondanelli; A Margutti; M R Ambrosio; A Valentini; M Campo; P Franceschetti; M C Zatelli; R Pansini; G Trasforini Journal: Neuroendocrinology Date: 1996-11 Impact factor: 4.914
Authors: Michael Ewers; Cathal Walsh; John Q Trojanowski; Leslie M Shaw; Ronald C Petersen; Clifford R Jack; Howard H Feldman; Arun L W Bokde; Gene E Alexander; Philip Scheltens; Bruno Vellas; Bruno Dubois; Michael Weiner; Harald Hampel Journal: Neurobiol Aging Date: 2010-12-14 Impact factor: 4.673
Authors: John G Csernansky; Hongxin Dong; Anne M Fagan; Lei Wang; Chengjie Xiong; David M Holtzman; John C Morris Journal: Am J Psychiatry Date: 2006-12 Impact factor: 18.112
Authors: Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens Journal: Lancet Neurol Date: 2007-08 Impact factor: 44.182
Authors: Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam Boxer; Kaj Blennow; Leah F Friedman; Douglas R Galasko; Marek Jutel; Anna Karydas; Jeffrey A Kaye; Jerzy Leszek; Bruce L Miller; Lennart Minthon; Joseph F Quinn; Gil D Rabinovici; William H Robinson; Marwan N Sabbagh; Yuen T So; D Larry Sparks; Massimo Tabaton; Jared Tinklenberg; Jerome A Yesavage; Robert Tibshirani; Tony Wyss-Coray Journal: Nat Med Date: 2007-10-14 Impact factor: 53.440
Authors: David R Riddell; Hua Zhou; Kevin Atchison; Helen K Warwick; Peter J Atkinson; Julius Jefferson; Lin Xu; Suzan Aschmies; Yolanda Kirksey; Yun Hu; Erik Wagner; Adrienne Parratt; Jane Xu; Zhuting Li; Margaret M Zaleska; J Steve Jacobsen; Menelas N Pangalos; Peter H Reinhart Journal: J Neurosci Date: 2008-11-05 Impact factor: 6.167
Authors: A Hye; S Lynham; M Thambisetty; M Causevic; J Campbell; H L Byers; C Hooper; F Rijsdijk; S J Tabrizi; S Banner; C E Shaw; C Foy; M Poppe; N Archer; G Hamilton; J Powell; R G Brown; P Sham; M Ward; S Lovestone Journal: Brain Date: 2006-11 Impact factor: 13.501
Authors: Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski Journal: Acta Neuropathol Date: 2014-01-03 Impact factor: 17.088
Authors: Sid E O'Bryant; Leigh Johnson; Melissa Edwards; Holly Soares; Michael D Devous; Sarah Ross; Geoffrey Rohlfing; James Hall Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472